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Summary
This study revisited the Dohner prognostic hierarchy in a cohort of 1585
well-documented patients with chronic lymphocytic leukaemia. The dura-
tion of both time to first treatment (TTFT) and overall survival (OS) were
significantly longer than observed previously, and this is at least partly due
to improved therapeutic options. Deletion 13q remains the most favourable
prognostic group with median TTFT and OS from fluorescence in situ
hybridization (FISH) testing of 72 months and >12 years, respectively.
Deletion 11q had the poorest median TTFT (22 months) and 17p deletion
the poorest median OS (5 years). The percentages of abnormal nuclei were
significantly associated with differential TTFT for the trisomy 12, 13q and
17p deletion cohorts but not for the 11q deletion cohort. From the date of
the first FISH study, patients with >85% 13q deletion nuclei had a notably
shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had
longer median TTFT and OS from the date of the first FISH study
(44 months and 11 years), and were more likely to be IGHV mutated.
Keywords: chronic lymphocytic leukaemia, cytogenetics, leukaemia, fluores-
cence in situ hybridization.
For more than 15 years the Dohner hierarchical classification
(Dohner et al, 2000), using fluorescence in situ hybridization
(FISH) probes to identify trisomy 12 and deletions at
13q14.2-q14.3 (including DLEU2, MIR15A/MIR16-1), 11q22.3
(ATM) and 17p13.1 (TP53) has been the gold standard for
the genetic characterization and assessment of prognosis for
patients with chronic lymphocytic leukaemia (CLL). The
Dohner classification has been validated by several groups
(Dewald et al, 2003; Geisler et al, 2009). Given the clinical
usefulness of the common recurring FISH detectable events
found by the probes encompassing the Dohner hierarchy used
to assess CLL patients, this genetic approach is used through-
out the world. Its benefits are primarily to provide prognostic
information for the clinician. Importantly, the FISH panel
data can be used to counsel these patients, whether in early or
more progressive disease status. In this era of utilization of
highly effective chemoimmunotherapy, it is uncertain whether
the original prognostic association is maintained between
FISH patterns and clinical outcome variables. To investigate
this, we took advantage of a robust clinical database that is
part of the Chronic Lymphocytic Leukemia Research Consor-
tium (CRC), a programme project dedicated to the conduct
of basic and translational research in CLL. The CRC is com-
posed of six active academic sites with significant numbers of
CLL patients and each site is a source of CLL samples and
highly detailed clinical information that are contributed to
the CRC database. The CRC tissue bank and clinical database
have been the source of multiple important published insights
into the utility of prognostic markers in CLL (Rassenti et al,
2008; Visone et al, 2011; Claus et al, 2014).
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We present here an assessment of the relationship between
the common recurring FISH-detectable genomic defects and
CLL clinical outcome using the CRC multi-institutional CLL
cohort. This analysis included primarily a reassessment of the
Dohner hierarchical classification (Dohner et al, 2000) and
its associations with time to first treatment (TTFT) and over-
all survival (OS).
Methods
Clinical database
All the clinical data were captured via the CRC Tissue-Core-
Management-System (TCMS). We used closed data fields
captured by the TCMS from all CRC investigators to assess
the date of diagnosis, date of initial treatment and clinical
status of each patient (Rassenti et al, 2008). A multiple
closed unique patient identifier system was used that com-
plied with the Health Insurance Portability and Accountabil-
ity Act.
Patient cohort
We identified 1585 CLL patients in the CRC database for
whom a complete FISH panel and relevant clinical data were
available. Patients were diagnosed between 1972 and 2011;
the most recent clinical follow-up was in 2012. Blood sam-
ples were collected from consenting CLL patients who satis-
fied the diagnostic criteria for CLL and were enrolled in the
CRC biorepository as per protocol approved by the Institu-
tional Review Board (IRB 080918). FISH analyses were per-
formed between 1998 and 2012. All of the CLL patients
tested were negative for a CCND1/IGH fusion, thus ruling
out the presence of mantle cell lymphoma.
FISH panel approach
All six participating CRC centres used standardized FISH
panels as described previously (Smoley et al, 2010). For 59 of
the 1585 patient samples, FISH analysis was done using cells
harvested after cell culture stimulated with CpG oligonu-
cleotide; the rest were harvested directly or after brief cell
culture without mitogen. Thresholds used to designate
17p13.1 (17p) deletion, 11q22.3 (11q) deletion, trisomy 12,
and 13q14.2-q14.3 (13q) deletion were: ≥5%, ≥5%, ≥125%
and ≥7%, respectively.
Statistical analysis
Demographic and clinical characteristics, including FISH
abnormality, according to the Dohner hierarchical classifica-
tion (Dohner et al, 2000) were summarized as number and
percentage for categorical variable and median with
interquartile ranges for continuous variables. Time to first
treatment (TTFT) was measured either from the date of
diagnosis (TTFT-DX) or from the date of the initial FISH
results (TTFT-FISH) to initiation of first treatment. Patients
who remained untreated at the time of analysis were cen-
sored on the date last confirmed to be without initiation of
therapy. OS was calculated from either the date of the CLL
diagnosis (OS-DX) or the date of the initial FISH study (OS-
FISH) to the date of death or censored on the last known
date alive. Kaplan–Meier estimates were used to summarize
time to event data. The log rank test was used to assess the
associations between FISH abnormality and TTFT and OS. P
values < 005 were considered statistically significant.
To be consistent with the selection criteria in the original
Dohner analysis (Dohner et al, 2000), we examined TTFT-
DX and OS-DX in patients for whom FISH was done within
4 years of diagnosis. This subset of patients was, by design,
the primary analysis cohort. We also examined the two clini-
cal endpoints from the date of the initial FISH analysis for
the entire cohort of 1585 patients (TTFT-FISH and OS-
FISH), which permitted us to assess the performance of FISH
testing completed at a time point not associated with diagno-
sis. To further clarify the prognostic value of FISH, we con-
ducted additional analyses after excluding patients for whom
treatment was initiated less than 14 d after the initial FISH
analysis, reasoning that FISH results were not available at the
time that the decision to treat was made.
We also evaluated the association between the percentage
of abnormal nuclei and both TTFT and OS for each FISH cat-
egory using the log rank test. Using 15% increments for each
FISH abnormality where feasible, we compared the outcomes
of patients with increasing specific FISH defect burdens with
those with a normal FISH result. Dohner FISH hierarchical
order (Dohner et al, 2000) was further used to categorize for
11q deletion, trisomy 12 and 13q deletion in patients with
17p deletion. Fisher’s exact test was used to assess the associa-
tion of percentage of 17p deletion with other FISH anomaly
by hierarchical order and IGHV mutation status.
Results
Distribution of FISH categories
Within the cohort of 1585 patients, 1048 had FISH testing
performed within 4 years of diagnosis. The distribution of
patients by FISH category did not differ between those diag-
nosed more than or less than 4 years prior to FISH testing
(P = 014; Table I). Although we preserved the structure of
the Dohner study (FISH within 4 years of diagnosis, inclu-
sion of previously treated patients), the distribution of FISH
results within the CRC differed from those reported in the
325 patients studied by Dohner (P < 0001). The CRC
cohort includes 12% with 17p deletion, 11% with 11q dele-
tion and 24% with trisomy 12, compared to the 7%, 17%,
and 18% reported by Dohner et al (2000).
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TTFT for patients from the date of their diagnosis
(TTFT-DX)
The TTFT from diagnosis was examined in the cohort of
1048 patients whose FISH analyses were performed within
4 years of diagnosis. Treatment status was unavailable for
three patients. As anticipated, median time to first treatment
was most favourable for those with sole 13q deletion
(72 months), followed by normal FISH (35 months) and tri-
somy 12 (30 months). The median TTFT of 22 months was
similar for those with 11q deletion and 17p deletion
(Table II and Fig 1).
OS for patients from the date of their diagnosis (OS-
DX)
For the patients with FISH analysis done within 4 years of
diagnosis, OS was most favourable for the 13q deletion cate-
gory, followed by normal FISH, trisomy 12, 11q deletion and
then 17p deletion (Table III and Fig 1). The median survival
was not reached for the 13q deletion and normal FISH
cohorts, whereas median OS was 8 years for the 11q deletion
cohort and 6 years for the 17p deletion group.
TTFT for patients from the date at which FISH was
performed (TTFT-FISH)
To evaluate the prognostic value of FISH from the date of
the FISH study, even when the analysis was not done
within 4 years of diagnosis, those patients (N = 404) whose
FISH analysis was obtained after the initiation of first treat-
ment was excluded from the entire cohort of 1585 patients
(N studied = 1181). For this group, the median time to
treatment was more favourable for those with sole 13q dele-
tion (64 months) followed by normal FISH (30 months),
trisomy 12 (14 months) and 17p deletion (10 months), and
was significantly worse for those with 11q deletion
(5 months) (Table IV and Fig 2). For some patients, the
first FISH analysis was performed at the same time when
they received treatment, and thus the treatment decision
was based on concurrent clinical evidence of worsening of
disease rather than the prognostic influence of the FISH
results. For this reason, we also excluded 220 patients who
were treated within 14 d of the FISH analysis, and exam-
ined TTFT from the date of when the FISH analysis was
performed for the remaining 961 patients. The results sug-
gested similar findings to those that included all patients
with FISH analysis done prior to initiation of first treat-
ment (data not shown).
OS for patients from the date at which FISH is
performed (OS-FISH)
We also evaluated survival from time of FISH analysis for
the entire cohort of patients with available FISH data
(N = 1585). Patients with 13q deletion had the most favour-
able OS, and the median OS was not reached. The median
OS for patients with normal cytogenetics was also not
reached. The patients with trisomy 12 had a median OS of
11 years. Patients with 11q deletion had a median survival of
6 years and those with 17p deletion had the poorest median
survival (4 years) (Table V and Fig 2).
Association of the percentage of abnormal nuclei on
TTFT and OS from when FISH analysis was performed
Here we studied if the extent of each FISH detectable defect
is related to clinical outcome. The median and range of per-
centages of abnormal nuclei for each FISH abnormality are
provided in Table VI. We found that the number of patients
was not always distributed evenly by percentage of abnormal
nuclei (Table VII). For example, 59 of 120 patients (49%)
from the 17p deletion group exhibited ≤20% abnormal
nuclei and only 14 (%) had between 20% and 50% abnormal
nuclei (Table VII). Similarly, 42% of patients with sole 13q
deletion had >70% abnormal nuclei.
For the 11q deletion, there was no significant difference in
median TTFT by the percentage of abnormal nuclei, whereas
trends in TTFT were observed for trisomy 12, 13q deletion
Table I. The distribution of patients by FISH category using the
Dohner classification, for the entire cohort of 1585 CLL patients and
for those with FISH testing within 4 years of diagnosis (N = 1048).
Entire cohort
FISH within
4 years of
diagnosis
N = 1585 N = 1048
N % N %
17p deletion 193 12 122 12
11q deletion 187 12 114 11
Trisomy 12 205 13 149 14
Normal 376 24 252 24
13q deletion 624 39 411 39
FISH, fluorescence in situ hybridization.
Table II. Association of FISH category and time to first treatment
from diagnosis for patients who had FISH testing done less than
4 years after diagnosis of chronic lymphocytic leukaemia
(N = 1045).
N Treated (n)
Median
TTFT–DX
(months) P-value
FISH category
17p deletion 122 93 22 <00001
11q deletion 113 92 22
Trisomy 12 148 113 30
Normal 252 164 35
13q deletion 411 183 72
FISH, fluorescence in situ hybridization; TTFT-DX, time to first
treatment measured from the date of diagnosis.
FISH Prognostic Classification of CLL Revisited
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and 17p deletion. The percentage of 13q deletion nuclei was
significantly associated with TTFT in the time from when
FISH analysis was performed (P < 00001, Table VII and
Fig 3) For 13q deletion, patients who exhibited >85% abnor-
mal nuclei had a shorter TTFT from time of FISH analysis
(24 months), similar to those with normal FISH and in con-
trast to those patients who had <85% abnormal nuclei
(52 months to median not reached) (P < 00001). There was
no significant association between percentage of 13q deletion
nuclei and IGHV mutation status (P = 01).
The percentage of 17p deletion nuclei was significantly
associated with TTFT from when FISH analysis was per-
formed (P = 0002, Table VII and Fig 4). Patients with
≤20% abnormal nuclei had a significantly longer TTFT from
diagnosis (44 months) than did those with >20% abnormal
nuclei: 1 month for the 20–65% group, 8 months for the
65–80% group and 1 month for >85% (P < 00001). To fur-
ther assess the TTFT for the cohort who had >20% abnormal
we categorized them into 4 groups (described in methods)
and examined the TTFT, but we were unable to find any fur-
ther cut-off point that was significantly different from the
20% cut-off (data not shown). However, the percentage of
17p deletion using the >20% deletion nuclei was significantly
associated with OS in time from initial FISH analysis
(P < 00001). As with TTFT, patients with ≤20% 17p dele-
Fig 1. Time to first treatment and overall sur-
vival by FISH category for patients who had
FISH analysis less than 4 years after diagnosis
of chronic lymphocytic leukaemia. FISH, fluo-
rescence in situ hybridization; Dx, diagnosis.
Table III. Association of FISH category and overall survival (OS)
from diagnosis for patients who had FISH testing done less than
4 years after diagnosis of chronic lymphocytic leukaemia
(N = 1048).
N Death (n)
Median
OS-DX (years)* P-value
FISH category
17p deletion 122 60 5 <00001
11q deletion 114 36 7
Trisomy 12 149 25 11
Normal 252 35 Not reached
13q deletion 411 35 Not reached
FISH, fluorescence in situ hybridization; OS-DX, overall survival
from the date of diagnosis. *[Correction added on 29 February 2016,
after online publication: this has been corrected to years].
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tion nuclei had a longer OS of 11 years compared to median
OS of 3 years for those with ≥20% 17p deletion nuclei.
The percentage of trisomy 12 nuclei was significantly asso-
ciated with TTFT from when FISH analysis was performed
(P = 003, Table VII). Patients with > 60% of abnormal tri-
somy 12 nuclei appeared to have shorter TTFT (P < 00001).
The Dohner hierarchical order for 11q deletion, trisomy
12 and 13q deletion (Dohner et al, 2000) was further applied
to patients with 17p deletion. For instance, if a patient had
11q deletion along with 17p this patient was then categorized
as having 11q deletion when assessing association of percent-
age of 17p deletion with other FISH anomalies by hierarchi-
cal order. There was no significant association observed
between percentage of 17p deletion and other FISH anoma-
lies summarized by hierarchical order. However there was a
significant association between percentage of abnormal 17p
nuclei and IGHV mutation status (Table VIII); patients with
≤20% 17p deletion nuclei were more likely than those with
≥20% 17p deletion nuclei to have mutated IGHV status
(51% vs. 25%, P = 0005).
Discussion
We employed a cohort of 1585 patients diagnosed with CLL
to revisit the FISH-based prognostic hierarchy described by
Dohner et al (2000) based on their population sample of 325
CLL patients. By comparison, although the FISH hierarchy
Table IV. Association of FISH category and time to first treatment
from the time of FISH testing (N = 1181).
N Treated (n)
Median
TTFT–FISH
(months) P-value
FISH category
17p deletion 120 80 10 <00001
11q deletion 124 102 3
Trisomy 12 163 123 14
Normal 266 154 30
13q deletion 508 224 64
FISH, fluorescence in situ hybridization; TTFT-FISH, time to first
treatment from the date of the initial FISH results.
Fig 2. Time to first treatment and overall sur-
vival by FISH category from the date when
FISH analysis was done. FISH, fluorescence
in situ hybridization.
FISH Prognostic Classification of CLL Revisited
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remains similar when OS is considered, the TTFT and OS
appears more favourable than originally reported. This clini-
cal trend is, of course, compatible with the enhanced ability
to treat CLL patients more effectively with chemoim-
munotherapy over the time frame of our study.
The FISH hierarchy remained consistent for all patients in
our CRC cohort, as well as when excluding patients whose
FISH analysis was done at the time of treatment. Our major
findings also include that, within the FISH hierarchy, 11q
deletion patients had the shortest TTFT, and a shorter TTFT
was observed with increasing numbers of abnormal inter-
phase nuclei exhibiting either 13q or 17p deletion.
The patients with 13q deletion clearly comprised the
most favourable prognostic group. TTFT for the normal
FISH category fell consistently between the 13q deletion and
the trisomy 12 and 11q deletion groups. Although the med-
ian TTFT from diagnosis was similar (Table II and Fig 1),
the 11q deletion patients tended to fare more poorly than
the 17p group after the median was reached (22 months).
Thereafter, TTFT was similar for the 17p deletion and tri-
somy 12 groups. In a somewhat striking deviation from the
Dohner hierarchy, when we excluded patients who received
treatment shortly after the initial FISH analysis, TTFT was
more favourable for those with a 17p deletion than for
those with either an 11q deletion or trisomy 12. We suggest,
along with others (Davids et al, 2015), that using the date
of the first FISH study offers a more objective analysis of
TTFT and OS than that obtained using the date of diagno-
sis of CLL.
For OS, the 17p deletion patients fared most poorly until
approximately 7 years of follow-up, whereupon the 11q dele-
tion patients tended to exhibit a similar unfavourable sur-
vival, and these two groups exhibited dramatically poorer
survival than did the other three hierarchical categories.
Although the median OS for trisomy 12 was 10–11 years in
comparison with the normal FISH group, their Kaplan–
Meier survival curves followed similar trajectories (see Figs 1
and 2). As with TTFT, the 13q deletion group exhibited the
most favourable prognosis, with roughly 75% of these
patients alive at 10 years post-diagnosis and post-initial FISH
testing.
We also examined TTFT for each FISH category by the
percentage of abnormal nuclei. Here, we found that the
prognosis was more favourable when the percentage of 17p
deletion nuclei was low, consistent with the findings of Tam
et al (2009). For deletion 13q, the prognosis was less favour-
able when the percentage of abnormal nuclei was high, and
this held whether TTFT was observed from diagnosis or from
the date of the initial FISH analysis. In another deviation
from the Dohner hierarchy (Dohner et al, 2000), patients
Table V. Association of FISH category and overall survival (OS)
from time of FISH testing (N = 1585).
N Death (n)
Median
OS–FISH (years)* P-value
FISH category
17p deletion 193 93 4 <00001
11q deletion 187 65 6
Trisomy 12 205 45 10
Normal 376 63 Not reached
13q deletion 624 81 Not reached
FISH, fluorescence in situ hybridization; OS-FISH, time to first treat-
ment from the date of diagnosis. *[Correction added on 29 February
2016, after online publication: this has been corrected to years].
Table VI. Percentage of abnormal nuclei for each FISH category
(N = 1585).
N Median (%)
Interquartile
range Range
FISH anomaly
17p deletion 193 385 (105%, 76%) (5%, 995%)
11q deletion 187 70 (345%, 87%) (65%, 100%)
Trisomy 12 205 55 (265%, 72%) (25%, 94%)
13q deletion 624 648 (38%, 84%) (7%, 100%)
FISH, fluorescence in situ hybridization.
Table VII. Association of percentage of abnormal nuclei and time to
first treatment from the time of FISH testing.
N (%) Treated
Median
TTFT
(months) P-value
% of 17p – (Fig 4)
5–20% 59 (49) 33 44 0002
20–50% 14 (12) 10 1
50–65% 15 (13) 12 1
65–80% 11 (9) 8 8
>80% 21 (18) 17 1
% of 11q –
5–20% 13 (10) 11 2 096
20–35% 18 (15) 15 3
35–50% 12 (10) 8 3
50–65% 16 (13) 15 2
65–80% 24 (19) 21 3
>80% 41 (33) 32 3
% of trisomy 12
15–15% 23 (14) 15 54 003
15–30% 17 (10) 10 30
30–45% 19 (12) 14 15
45–60% 29 (18) 22 29
60–75% 44 (27) 34 7
>75% 31 (19) 28 3
% of 13q – (Fig 3)
7–25% 78 (15) 26 Not reached <00001
25–40% 54 (11) 17 85
40–55% 81 (16) 31 89
55–70% 80 (16) 32 71
70–85% 111 (22) 53 52
>85% 104 (20) 65 24
FISH, fluorescence in situ hybridization; TTFT, time to first treat-
ment.
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with 5–20% 17p deletion nuclei exhibited a very favourable
44 and 57 months of TTFT from time of FISH analysis and
diagnosis, which was comparable to TTFT of the 13q dele-
tion patients as a group. In contrast, patients with the high-
est percentage of 13q deletion nuclei (>85%) exhibited a
much less favourable TTFT than those with fewer than 85%
nuclei with 13q deletion. Those with >85% 13q deletion
nuclei exhibited a TTFT more comparable to those with a
normal FISH pattern or trisomy 12, and this is similar to
earlier observations (Van Dyke et al, 2010; Dal Bo et al,
2011). In contrast to 17p and 13q deletion groups, patients
with 11q deletion did not exhibit a statistically significant
association between TTFT and percentage of abnormal
nuclei. Thus, we were unable to confirm an association
between high percentage 11q deletion and adverse outcomes
reported by Marasca et al (2013) and Jain et al (2015). Simi-
larly, we were unable to confirm an association between
small clones with TP53 mutation and poor survival (Rossi
et al, 2014), assuming that small clones with TP53 mutation
Fig 3. Association of percentage of 13q dele-
tion nuclei and TTFT from when FISH analysis
was done. FISH, fluorescence in situ hybridiza-
tion; TTFT, time to first treatment.
Fig 4. Association of percentage of 17p dele-
tion nuclei and TTFT from when FISH analysis
was done. FISH, fluorescence in situ hybridiza-
tion; TTFT, time to first treatment.
Table VIII. Other FISH anomalies and IGHV mutation status by
percentage of 17p deletion in patients with 17p deletion.
% of 17p abnormal
nuclei
P-value≤20% >20%
FISH hierarchical excluding 17p deletion
11q deletion 7 6 044
Trisomy 12 9 7
Normal 10 18
13q deletion 33 30
Other FISH anomalies
11q deletion 7 6
Trisomy 12 10 8
13q deletion 40 36
IGHV mutations status
Mutated 30 15 0005
Unmutated 29 46
FISH, fluorescence in situ hybridization.
FISH Prognostic Classification of CLL Revisited
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are comparable to our patients with FISH detectable but low
percentages of 17p deletion. It was not possible to carry out
a similar analysis for an association between OS and percent-
age of abnormal nuclei, because the survival data are not suf-
ficiently mature in our CRC database. It is our intent to
conduct further analyses on the relationship of abnormal
nuclei as the clinical data mature.
In terms of our study, the results are most applicable to
patients with CLL whose FISH analysis is done within
4 years of diagnosis and prior to starting therapy. Sequential
evaluation of genetic defects via FISH or with more detailed
sequencing methods will be of great interest in monitoring
clinical progression in CLL, and clonal genetic abnormalities
in CLL have been shown to evolve and change over time
(Shanafelt et al, 2006; Braggio et al, 2012; Chuang et al,
2012; Landau et al, 2013; Ouillette et al, 2013; Ojha et al,
2015). Changes in prognosis upon disease progression associ-
ated with cytogenetic evolution (Guieze & Wu, 2015) high-
light the association of clinical features with specific genetic
changes. Future studies of genetic changes over time using a
large and well annotated clinical cohort of CLL patients will
be required to understand the potential benefits of chromo-
somal microarray, selected gene sequencing platforms, or
deep sequencing of whole genomes for a more complete
understanding of prognosis and new therapeutic targets in
CLL (Edelmann et al, 2012; Rossi et al, 2013; Baliakas et al,
2015; Puente et al, 2015).
Limitations of our study include that the cohort consisted
of patients who were referred or self-referred to these six aca-
demic institutions. However the large size of this cohort is
likely to reflect the overall CLL patient base. We have
assumed that the improvements in outcome for patients who
are assessed via FISH testing are probably due to the dra-
matic impact of chemoimmunotherapy on patient outcome.
However our database does not include the specific therapies
that each patient received and thus we cannot know what
percentages of patients received these treatments. It is also
unlikely that there were significant percentages of CLL
patients who received the more novel targeted signal inhibi-
tors now being widely tested as this study analyses only used
data acquired prior to 2011.
In summary our updated data on this large cohort of CLL
cases validates the Dohner hierarchy (Dohner et al, 2000).
The duration of both TTFT and survival are estimated to be
considerably longer than during the years of the Dohner
study, probably because of the much more effective combina-
tion therapies instituted over the last 20 years. We also
observed that the percentage of abnormal nuclei is an impor-
tant prognostic variable. Finally, we found that the FISH
panel commonly used by CLL practitioners remains a valu-
able prognostic tool even as the therapeutic options change
for our CLL patients.
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